Dr. Reddy’s Laboratories Ltd ADR - Asset Resilience Ratio
Dr. Reddy’s Laboratories Ltd ADR (RDY) has an Asset Resilience Ratio of 11.36% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Dr. Reddy’s Laboratories Ltd ADR to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Dr. Reddy’s Laboratories Ltd ADR's Asset Resilience Ratio has changed over time. See Dr. Reddy’s Laboratories Ltd ADR balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Dr. Reddy’s Laboratories Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RDY market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $63.93 Billion | 11.36% |
| Total Liquid Assets | $63.93 Billion | 11.36% |
Asset Resilience Insights
- Moderate Liquidity: Dr. Reddy’s Laboratories Ltd ADR has 11.36% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Dr. Reddy’s Laboratories Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Dr. Reddy’s Laboratories Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Dr. Reddy’s Laboratories Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 9.28% | $45.76 Billion | $492.99 Billion | -10.58pp |
| 2024-03-31 | 19.86% | $76.96 Billion | $387.52 Billion | +1.55pp |
| 2023-03-31 | 18.31% | $58.95 Billion | $321.85 Billion | +8.21pp |
| 2022-03-31 | 10.10% | $29.59 Billion | $292.83 Billion | -6.03pp |
| 2021-03-31 | 16.14% | $586.04 Million | $3.63 Billion | +2.10pp |
| 2020-03-31 | 14.04% | $431.11 Million | $3.07 Billion | +4.00pp |
| 2019-03-31 | 10.04% | $22.64 Billion | $225.43 Billion | +1.47pp |
| 2018-03-31 | 8.57% | $19.34 Billion | $225.60 Billion | +0.92pp |
| 2017-03-31 | 7.65% | $16.82 Billion | $219.82 Billion | -9.22pp |
| 2016-03-31 | 16.87% | $35.03 Billion | $207.65 Billion | -0.72pp |
| 2015-03-31 | 17.59% | $34.26 Billion | $194.76 Billion | +2.85pp |
| 2014-03-31 | 14.74% | $25.08 Billion | $170.22 Billion | +2.82pp |
| 2013-03-31 | 11.91% | $169.63 Billion | $1.42 Trillion | +2.90pp |
| 2012-03-31 | 9.02% | $10.77 Billion | $119.48 Billion | +8.98pp |
| 2011-03-31 | 0.03% | $33.00 Million | $95.00 Billion | -5.16pp |
| 2010-03-31 | 5.19% | $4.17 Billion | $80.33 Billion | +4.56pp |
| 2009-03-31 | 0.63% | $530.00 Million | $83.79 Billion | -4.93pp |
| 2008-03-31 | 5.56% | $4.75 Billion | $85.45 Billion | +5.55pp |
| 2007-03-31 | 0.02% | $15.38 Million | $86.12 Billion | 0.00pp |
| 2006-03-31 | 0.02% | $14.70 Million | $68.77 Billion | -1.04pp |
| 2005-03-31 | 1.06% | $310.87 Million | $29.29 Billion | -8.47pp |
| 2004-03-31 | 9.53% | $2.54 Billion | $26.68 Billion | -28.32pp |
| 2003-03-31 | 37.85% | $8.71 Billion | $23.03 Billion | +37.85pp |
| 2002-03-31 | 0.00% | $516.00K | $18.95 Billion | 0.00pp |
| 2001-03-31 | 0.00% | $399.00K | $11.84 Billion | -2.47pp |
| 2000-03-31 | 2.47% | $3.84 Million | $155.57 Million | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more